|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Using the MiSeq™ system, plasma and matched tumor DNA samples were analyzed for hotspot mutations in the TERT, CTNNB1, and TP53 genes that had been verified as the most prevalent mutations in HCC.
|
27248174 |
2016 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Using in situ hybridization, the signal corresponding to beta-catenin gene exon 3 mRNA was particularly strong in cytoplasm of HCC when compared with those of paracancerous tissues and normal liver tissues.
|
11570580 |
2001 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Using HCC HepG2 cells we find that, on the one hand both protein and mRNA of KLF8 are up-regulated under Wnt3a stimulation, on the other hand overexpression of KLF8 increases the cytoplasm and nucleus accumulation of β-catenin, recruits p300 to β-catenin/T-cell factor 4 (TCF4) transcription complex, enhances TOP flash report gene transcription, and induces Wnt/β-catenin signaling target genes c-Myc, cyclin D1 and Axin1 expression.
|
22761862 |
2012 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
|
29027712 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Upregulation of MiR-212 Inhibits Migration and Tumorigenicity and Inactivates Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma.
|
29618288 |
2018 |
|
Liver carcinoma
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
Upregulation of FZD7 was associated with reduced phosphorylation of beta-catenin and led to nuclear accumulation in HCC tumors.
|
16098625 |
2005 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Unlike Nrf2 mutations, those of Ctnnb1, which are frequent in human HCC, were a later event as they appeared only in fully advanced HCCs (18.5%).
|
25783764 |
2015 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
UNC119 promotes the growth and migration of hepatocellular carcinoma via Wnt/β/catenin and TGF/β-EMT signaling pathways.
|
29552782 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
UNC119 promotes the growth and migration of hepatocellular carcinoma via Wnt/β-catenin and TGF-β/EMT signaling pathways.
|
29552781 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Two cases (one nodule-in-nodule case and another case with closely attached HCC and HGDN) showed several overlapped driver mutations (CTNNB1 and CEBPA) and CNAs (losses of CDKN2A, RB1, and TP53) between HGDNs and HCCs, suggesting their roles in the early HCC development.
|
29949741 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Tumor suppressor function of ezrin-radixin-moesin-binding phosphoprotein-50 through β-catenin/E-cadherin pathway in human hepatocellular cancer.
|
23483729 |
2013 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 and CTNNB1 are the next most prevalent mutations, affecting 25%-30% of HCC patients, that, in addition to low-frequency mutated genes (eg, AXIN1, ARID2, ARID1A, TSC1/TSC2, RPS6KA3, KEAP1, MLL2), help define some of the core deregulated pathways in HCC.
|
26099527 |
2015 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Total beta-catenin levels were higher than controls in most tumors; however, GS was exclusively increased in HCCs with mutations.
|
19101982 |
2009 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest that p28(GANK) expression is regulated by a positive feedback loop involving β-catenin, which may play a critical role in tumorigenesis and the progression of HCC.
|
21691299 |
2011 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
To study whether endogenous β-Catenin is required for c-Met/sgAxin1-driven HCC development, we expressed c-Met/sgAxin1 in liver-specific Ctnnb1 null mice, which completely prevented HCC development.
|
30737831 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the function(s) of SKP2 in HCC, we stably overexpressed the SKP2 gene in the mouse liver, either alone or in combination with activated forms of N-Ras (N-RasV12), AKT1 (myr-AKT1), or β-catenin (ΔN90-β-catenin) protooncogenes, via hydrodynamic gene delivery.
|
25537506 |
2015 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
To determine the relation, small interference RNA(siRNA) against beta-catenin was transfected into HCC cell line HepG(2), and cell cycle and cyclin A and cyclin E protein expression were detected.
|
19411833 |
2009 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
To compare the expression of genes involved in p53, Wnt/beta-catenin, and retinoblastoma (Rb) 1 pathways between cirrhosis-associated hepatocellular carcinoma (HCC-C) and hepatocellular carcinoma arising in non-cirrhotic liver (HCC-NC).
|
20546333 |
2010 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To ascertain the prevalence of deregulating mutations of beta-catenin gene, and to correlate this with the occurrence of 249(serine) p53 gene mutation and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma.
|
16121349 |
2005 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
To address beta-catenin's capability in maintaining the malignant phenotype in established pediatric HB and HCC cell lines, HuH-6 and HepG2, harboring mutated and overexpressed beta-catenin, we carried out a series of in vitro analyses through a transfection of short interfering RNAs (siRNAs) to generate a loss-of-function model.
|
16465377 |
2006 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, our results suggest a previously unknown Wnt/β catenin-miR-770-FBXW7 molecular network in the HCC development.
|
26602384 |
2016 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, heterogeneous β-catenin activation drives HCC initiation and persists throughout hepatocarcinogenesis.
|
31575545 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, beta-catenin is essential for the survival and growth of hepatoma cells independent of mutations in the beta-catenin gene and provide a proof of principle for the significance of the therapeutic inhibition of beta-catenin in HCC.
|
18030363 |
2007 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus alterations in the beta-catenin gene frequently are selected for during liver tumorigenesis and suggest that disregulation of the Wnt-beta-catenin pathway is a major event in the development of HCC in humans and mice.
|
9671767 |
1998 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
This was confirmed by RT-qPCR of an independent cohort of CTNNB1-mutated HCC and the suppression of the LKB1-related profile upon β-catenin silencing of CTNNB1-mutated human hepatoma cell lines.
|
30566242 |
2019 |